#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

News

srdce a diabetes

Diabetes mellitus and heart failure −⁠ interconnected units with complex pathogenesis

12. 1. 2023 Source: Heart Failure

Diabetes mellitus (DM) represents a significant risk factor for the development of heart failure. The pathogenesis of this condition is very complex, involving hyperglycemia and other metabolic abnormalities, as well as frequently occurring comorbidities such as hypertension, ischemic heart disease, or diabetic neuropathy. The development of type 2 DM (T2DM) in patients with heart failure (cardiogenic T2DM) is also quite common and is primarily caused by the resistance of peripheral tissues to insulin. The result of cardiogenic DM is further…

Teriflunomide "under the microscope" or what it's like to live with MS in the North

The Teri-LIFE study examined teriflunomide very comprehensively. How does it manage to affect the quality of life of patients with multiple sclerosis (MS) according to data from real clinical…

12. 1. 2023 Source: Multiple Sclerosis

kardiologie výzkum

Cardiovascular Interventions with Continued Therapy with Dabigatran −⁠ Insights from the GLORIA-AF Study

An analysis using data from an international registry of patients with newly diagnosed atrial fibrillation evaluated the safety and efficacy of continued therapy with dabigatran during cardioversion…

12. 1. 2023 Source: Anticoagulant Treatment

magnetická_rezonance

Smouldering Multiple Sclerosis: How Can MRI Help in Its Identification?

With the changing understanding of the etiopathogenesis of multiple sclerosis, several new questions arise. One of them is the question of identifying the progressive phase of the disease. Can…

4. 1. 2023 Source: Multiple Sclerosis

Teriflunomide vs. Dimethyl Fumarate: Does Their Classification into Different Treatment Lines Have Merit?

Teriflunomide is one of the first-choice medications in the treatment of multiple sclerosis (MS) patients, not only in the Czech Republic. Conversely, the use of dimethyl fumarate is more limited…

4. 1. 2023 Source: Multiple Sclerosis

nemocnice příjem čekárna

Prevalence of Heart Failure and Its Subtypes in the Population of Developed Countries

In developed countries, heart failure occurs in approximately 2% of the population, with an annual incidence of 5-10/1000 inhabitants. The mortality rate for patients with chronic heart failure is…

2. 1. 2023 Source: Heart Failure

Inclisiran −⁠ a new addition to the arsenal of dyslipidemia treatment

At the XXIX Congress of the Czech Society of Internal Medicine ČLS JEP, held November 6−9, 2022 in Prague, lectures on innovative dyslipidemia therapy using the small interfering RNA molecule −…

23. 12. 2022 Source: Chronic Heart Failure and Lipidology

LDL cholesterol

Use of Inclisiran in a Patient in Secondary Cardiovascular Prevention

Lowering LDL cholesterol (LDL-c) is one of the primary goals for reducing cardiovascular (CV) risk due to its proven mortality reduction. However, many patients with familial hypercholesterolemia or…

23. 12. 2022 Source: Chronic Heart Failure and Lipidology

fokální záchvaty

Cenobamate −⁠ A Case Study from Slovak Real Practice

Cenobamate is indicated for adjunctive therapy of focal seizures with or without secondary generalization in adult patients who have not achieved sufficient results with previous treatment with at…

23. 12. 2022 Source: Epilepsy

karcinom plic_lékař

Brigatinib in the Therapy of Pretreated Patients with Advanced ALK-Positive NSCLC

A French study analyzed clinical data of pretreated ALK-positive patients with advanced non-small cell lung cancer (NSCLC) and examined the efficacy of next-generation ALK inhibitors –⁠ brigatinib,…

22. 12. 2022 Source: Non-Small Cell Lung Cancer

1 … 54 55 56 57 58 … 170

Back Filter by speciality

#ADS_BOTTOM_SCRIPTS#